Unknown

Dataset Information

0

Preoperative Intensity-modulated Chemoradiation Therapy with Simultaneous Integrated Boost in Rectal Cancer: 2-year Follow-up Results of Phase II Study.


ABSTRACT: Background:The aim of the study was to investigate the feasibility and safety of experimental fractionation using intensity modulated radiation therapy with a simultaneous integrated boost (IMRT-SIB) to shorten the overall treatment time without dose escalation in preoperative radiochemotherapy of locally advanced rectal cancer. Patients and methods:Between January 2014 and November 2015, a total of 51 patients with operable stage II-III rectal adenocarcinoma were treated. The preoperative treatment with intensity modulated radiation therapy (IMRT) and a pelvic dose of 41.8 Gy and simultaneously delivered 46.2 Gy to T2/3 and 48.4 Gy to T4 tumour in 22 fractions, with standard concomitant capecitabine, was completed in 50 patients out of whom 47 were operated. The median follow-up was 35 months. Results:The rate of acute toxicity G ? 3 was 2.4%. The total downstaging rate was 89% and radical resection was achieved in 98% of patients. Pathologic complete response (pCR) was observed in 25.5% of patients, with 2-year local control (LC), disease free survival (DFS), and overall survival (OS) of 100% for this patient group. An intention-to-treat analysis revealed pN to be a significant prognostic factor for DFS and OS (P = 0.005 and 0.030, respectively). LC for the entire group was 100%, and 2-year DFS and OS were 90% (95 % CI 98.4-81.6) and 92.2% (95% CI 99.6-84.7), respectively. Conclusions:The experimental regime in this study resulted in a high rate of pCR with a low acute toxicity profile. Excellent early results translated into encouraging 2-year LC, DFS, and OS.

SUBMITTER: But-Hadzic J 

PROVIDER: S-EPMC5839078 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6707003 | BioStudies
2015-01-01 | S-EPMC4540628 | BioStudies
2020-01-01 | S-EPMC7541899 | BioStudies
2018-01-01 | S-EPMC5945520 | BioStudies
2017-01-01 | S-EPMC5721605 | BioStudies
2017-01-01 | S-EPMC5532702 | BioStudies
2013-01-01 | S-EPMC3840044 | BioStudies
2016-01-01 | S-EPMC5506712 | BioStudies
2016-01-01 | S-EPMC5216815 | BioStudies
2019-01-01 | S-EPMC6876219 | BioStudies